Phenytoin parahydroxylation is not impaired in patients with young-onset Parkinson's disease

https://doi.org/10.1016/0303-8467(94)90117-1Get rights and content

Abstract

Impaired hepatic detoxification capacity by cytochrome P450 subsystems has been implicated in the pathogenesis of Parkinson's disease. We have demonstrated that hepatic parahydroxylation of phenytoin (PHT) is impaired in patients with late-onset Parkinson's disease. In the present study, we have investigated the hypothesis that PHT parahydroxylation is even more impaired in patients with young-onset Parkinson's disease (age at onset before 40 years). We determined PHT parahydroxylation capacity in 21 patients with young-onset Parkinson's disease and 15 healthy age-matched controls. PHT parahydroxylation capacity was assessed by measuring the ratio of PHT to its major metabolite p-hydroxyphenyl-phenylhydantoin in serum 6 h after an oral test dose of 300 mg PHT. PHT parahydroxylation did not differ significantly between patients and controls. These results argue against the hypothesis that impaired activity of the cytochrome P450 isoenzyme responsible for PHT parahydroxylation is involved in the etiology of Parkinson's disease.

References (26)

  • M. Armstrong et al.

    Mutant debrisoquine hydroxylation genes in Parkinson's disease

    Lancet

    (1992)
  • C.A.D. Smith et al.

    Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease

    Lancet

    (1992)
  • J.W. Langston et al.

    Chronic parkinsonism in humans due to a product of meperidineanalog synthesis

    Science

    (1983)
  • Cited by (6)

    • Impaired hepatic function and central dopaminergic denervation in a rodent model of Parkinson's disease: A self-perpetuating crosstalk?

      2012, Biochimica et Biophysica Acta - Molecular Basis of Disease
      Citation Excerpt :

      Moreover, detoxification of medications and toxins is less efficient in PD patients compared to healthy individuals, thus possibly reflecting altered liver function [9]. Impaired capacity of hepatic P450 subsystems have been observed in late but not early onset PD patients [10,11] suggesting that hepatic alterations are not involved in the etiology of the disease but may emerge as a consequence of central neurodegenerative processes. Recent data indicate that brain dopaminergic systems represent an important center regulating hepatic cytochrome P450 activity [6,12,13].

    • Acetaldehyde and parkinsonism: Role of CYP450 2E1

      2013, Frontiers in Behavioral Neuroscience
    View full text